» Articles » PMID: 25593945

Recent Advances in Liver Resection for Hepatocellular Carcinoma

Overview
Journal Front Surg
Specialty General Surgery
Date 2015 Jan 17
PMID 25593945
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. The association of HCC with chronic liver disease (CLD) is well known and making treatment complex and challenging. The treatment of HCC must take into consideration, the severity of CLD, the stage of HCC, and the clinical condition of the patient. Liver resection (LR) is one of the most efficient treatments for patients with HCC. Better liver function assessment, increased understanding of segmental liver anatomy using more accurate imaging studies, and surgical technical progress are the important factors that have led to reduced mortality, with an expected 5 year survival of 38-61% depending on the stage of the disease. However, the procedure is applicable to <30% of all HCC patients, and 80% of the patients after LR recurred within 5 years. There are recent advances and prospects in LR for HCC in several aspects. Three-dimensional computed tomography imaging assisted preoperative surgical planning facilitates unconventional types of LR. Emerging evidences of laparoscopic hepatectomy and prospects for the use of newly developing chemotherapies as a combined therapy may lead to expanding indication of LR. LR and liver transplantation could be associated rather than considered separately with the current concepts of "bridging LR" and "salvage transplantation."

Citing Articles

Comparing a virtual reality head-mounted display to on-screen three-dimensional visualization and two-dimensional computed tomography data for training in decision making in hepatic surgery: a randomized controlled study.

Preukschas A, Wise P, Bettscheider L, Pfeiffer M, Wagner M, Huber M Surg Endosc. 2024; 38(5):2483-2496.

PMID: 38456945 PMC: 11078809. DOI: 10.1007/s00464-023-10615-8.


Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?.

Wu X, Lokken R, Mehta N JHEP Rep. 2023; 5(8):100781.

PMID: 37456674 PMC: 10339255. DOI: 10.1016/j.jhepr.2023.100781.


Hematoma Disguised as Cancer.

Garfinkel A, Nagourney A, Larson M Cureus. 2023; 15(5):e39665.

PMID: 37398808 PMC: 10307931. DOI: 10.7759/cureus.39665.


Salvage versus Primary Liver Transplantation for Hepatocellular Carcinoma: A Twenty-Year Experience Meta-Analysis.

Guerrini G, Esposito G, Olivieri T, Magistri P, Ballarin R, Di Sandro S Cancers (Basel). 2022; 14(14).

PMID: 35884526 PMC: 9320001. DOI: 10.3390/cancers14143465.


Ozone induces BEL7402 cell apoptosis by increasing reactive oxygen species production and activating JNK.

Tang S, Xu B, Li J, Zhong M, Hong Z, Zhao W Ann Transl Med. 2021; 9(15):1257.

PMID: 34532394 PMC: 8421928. DOI: 10.21037/atm-21-3233.


References
1.
Makuuchi M, Sano K . The surgical approach to HCC: our progress and results in Japan. Liver Transpl. 2004; 10(2 Suppl 1):S46-52. DOI: 10.1002/lt.20044. View

2.
Lai E, Fan S, Lo C, Chu K, Liu C, Wong J . Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg. 1995; 221(3):291-8. PMC: 1234572. DOI: 10.1097/00000658-199503000-00012. View

3.
Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K . Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134(7):1908-16. DOI: 10.1053/j.gastro.2008.02.091. View

4.
Fan S, Lai E, Lo C, Ng I, Wong J . Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg. 1995; 130(2):198-203. DOI: 10.1001/archsurg.1995.01430020088017. View

5.
Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View